Literature DB >> 32572726

Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.

Xiao-Fei Kong1,2, Lisa Worley3,4, Darawan Rinchai5, Vincent Bondet6,7, Puthen Veettil Jithesh5, Marie Goulet8, Emilie Nonnotte8, Anne Sophie Rebillat8, Martine Conte8, Clotilde Mircher8, Nicolas Gürtler9, Luyan Liu10, Mélanie Migaud10, Mohammed Elanbari5, Tanwir Habib5, Cindy S Ma3,4, Jacinta Bustamante10,11, Laurent Abel12,10, Aimé Ravel8, Stanislas Lyonnet13, Arnold Munnich14, Darragh Duffy6,7, Damien Chaussabel5, Jean-Laurent Casanova12,10,15,11,16, Stuart G Tangye3,4, Stéphanie Boisson-Dupuis12, Anne Puel10.   

Abstract

Down syndrome (DS) is characterized by the occurrence of three copies of human chromosome 21 (HSA21). HSA21 contains a cluster of four interferon receptor (IFN-R) genes: IFNAR1, IFNAR2, IFNGR2, and IL10RB. DS patients often develop mucocutaneous infections and autoimmune diseases, mimicking patients with heterozygous gain-of-function (GOF) STAT1 mutations, which enhance cellular responses to three types of interferon (IFN). A gene dosage effect at these four loci may contribute to the infectious and autoimmune manifestations observed in individuals with DS. We report high levels of IFN-αR1, IFN-αR2, and IFN-γR2 expression on the surface of monocytes and EBV-transformed-B (EBV-B) cells from studying 45 DS patients. Total and phosphorylated STAT1 (STAT1 and pSTAT1) levels were constitutively high in unstimulated and IFN-α- and IFN-γ-stimulated monocytes from DS patients but lower than those in patients with GOF STAT1 mutations. Following stimulation with IFN-α or -γ, but not with IL-6 or IL-21, pSTAT1 and IFN-γ activation factor (GAF) DNA-binding activities were significantly higher in the EBV-B cells of DS patients than in controls. These responses resemble the dysregulated responses observed in patients with STAT1 GOF mutations. Concentrations of plasma type I IFNs were high in 12% of the DS patients tested (1.8% in the healthy controls). Levels of type I IFNs, IFN-Rs, and STAT1 were similar in DS patients with and without recurrent skin infections. We performed a genome-wide transcriptomic analysis based on principal component analysis and interferon modules on circulating monocytes. We found that DS monocytes had levels of both IFN-α- and IFN-γ-inducible ISGs intermediate to those of monocytes from healthy controls and from patients with GOF STAT1 mutations. Unlike patients with GOF STAT1 mutations, patients with DS had normal circulating Th17 counts and a high proportion of terminally differentiated CD8+ T cells with low levels of STAT1 expression. We conclude a mild interferonopathy in Down syndrome leads to an incomplete penetrance at both cellular and clinical level, which is not correlate with recurrent skin bacterial or fungal infections. The constitutive upregulation of type I and type II IFN-R, at least in monocytes of DS patients, may contribute to the autoimmune diseases observed in these individuals.

Entities:  

Keywords:  Down syndrome; JAK-STAT; interferon receptors; interferonopathy

Year:  2020        PMID: 32572726      PMCID: PMC7418179          DOI: 10.1007/s10875-020-00803-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  48 in total

1.  Mortality and life-table in Down's syndrome.

Authors:  J Oster; M Mikkelsen; A Nielsen
Journal:  Acta Paediatr Scand       Date:  1975-03

Review 2.  Chromosome 21 and down syndrome: from genomics to pathophysiology.

Authors:  Stylianos E Antonarakis; Robert Lyle; Emmanouil T Dermitzakis; Alexandre Reymond; Samuel Deutsch
Journal:  Nat Rev Genet       Date:  2004-10       Impact factor: 53.242

3.  Prevalence and Description of Hidradenitis Suppurativa in Down Syndrome: A Cross-sectional Study of 783 Subjects.

Authors:  Florence Poizeau; Emilie Sbidian; Clotilde Mircher; Anne-Sophie Rebillat; Olivier Chosidow; Pierre Wolkenstein; Aimé Ravel; Claire Hotz
Journal:  Acta Derm Venereol       Date:  2019-03-01       Impact factor: 4.437

4.  Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease.

Authors:  Xiao-Fei Kong; Guillaume Vogt; Yuval Itan; Anna Macura-Biegun; Anna Szaflarska; Danuta Kowalczyk; Ariane Chapgier; Avinash Abhyankar; Dieter Furthner; Claudia Djambas Khayat; Satoshi Okada; Vanessa L Bryant; Dusan Bogunovic; Alexandra Kreins; Marcela Moncada-Vélez; Mélanie Migaud; Sulaiman Al-Ajaji; Saleh Al-Muhsen; Steven M Holland; Laurent Abel; Capucine Picard; Damien Chaussabel; Jacinta Bustamante; Jean-Laurent Casanova; Stéphanie Boisson-Dupuis
Journal:  Hum Mol Genet       Date:  2012-11-16       Impact factor: 6.150

5.  A Prevalent CXCR3+ Phenotype of Circulating Follicular Helper T Cells Indicates Humoral Dysregulation in Children with Down Syndrome.

Authors:  Giorgio Ottaviano; Jolanda Gerosa; Micaela Santini; Pasqualina De Leo; Andrea Vecchione; Tatiana Jofra; Cristiana Trimarchi; Maurizio De Pellegrin; Massimo Agosti; Alessandro Aiuti; Maddalena Marinoni; Maria Pia Cicalese; Georgia Fousteri
Journal:  J Clin Immunol       Date:  2020-01-28       Impact factor: 8.317

6.  Characterization of Staphylococcus aureus infections in children with Down syndrome.

Authors:  Jeffrey N Johnston; Sheldon L Kaplan; Edward O Mason; Kristina G Hulten
Journal:  J Infect Chemother       Date:  2015-09-18       Impact factor: 2.211

Review 7.  Dermatological aspects of the S2k guidelines on Down syndrome in childhood and adolescence.

Authors:  Regina Fölster-Holst; Tilman Rohrer; Anna-Maria Jung
Journal:  J Dtsch Dermatol Ges       Date:  2018-10       Impact factor: 5.584

8.  Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.

Authors:  Angela L Rachubinski; Belinda Enriquez Estrada; David Norris; Cory A Dunnick; Jennifer C Boldrick; Joaquin M Espinosa
Journal:  JAAD Case Rep       Date:  2019-04-05

9.  Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity.

Authors:  Paula Araya; Katherine A Waugh; Kelly D Sullivan; Nicolás G Núñez; Emiliano Roselli; Keith P Smith; Ross E Granrath; Angela L Rachubinski; Belinda Enriquez Estrada; Eric T Butcher; Ross Minter; Kathryn D Tuttle; Tullia C Bruno; Mariana Maccioni; Joaquín M Espinosa
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-07       Impact factor: 11.205

10.  Oral Candidal and Streptococcal carriage in Down syndrome patients.

Authors:  Gouse Mohiddin; Aravindha Babu Narayanaswamy; K M K Masthan; Anitha Nagarajan; Abikshyeet Panda; Shyam Sundar Behura
Journal:  J Nat Sci Biol Med       Date:  2015 Jul-Dec
View more
  12 in total

Review 1.  Infections in the monogenic autoimmune syndrome APECED.

Authors:  Vasileios Oikonomou; Timothy J Break; Sarah L Gaffen; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Curr Opin Immunol       Date:  2021-08-18       Impact factor: 7.268

2.  COVID-19 and Down syndrome: the spark in the fuel.

Authors:  Manini Majithia; Susan P Ribeiro
Journal:  Nat Rev Immunol       Date:  2022-07       Impact factor: 108.555

3.  Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder.

Authors:  Jonathan D Santoro; Rebecca Partridge; Runi Tanna; Dania Pagarkar; Mellad Khoshnood; Mustafa Rehmani; Ryan M Kammeyer; Grace Y Gombolay; Kristen Fisher; Allison Conravey; Jane El-Dahr; Alison L Christy; Lina Patel; Melanie A Manning; Heather Van Mater; Michael S Rafii; Eileen A Quinn
Journal:  J Neurodev Disord       Date:  2022-06-03       Impact factor: 4.074

4.  Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.

Authors:  Timothy J Break; Vasileios Oikonomou; Nicolas Dutzan; Jigar V Desai; Marc Swidergall; Tilo Freiwald; Daniel Chauss; Oliver J Harrison; Julie Alejo; Drake W Williams; Stefania Pittaluga; Chyi-Chia R Lee; Nicolas Bouladoux; Muthulekha Swamydas; Kevin W Hoffman; Teresa Greenwell-Wild; Vincent M Bruno; Lindsey B Rosen; Wint Lwin; Andy Renteria; Sergio M Pontejo; John P Shannon; Ian A Myles; Peter Olbrich; Elise M N Ferré; Monica Schmitt; Daniel Martin; Daniel L Barber; Norma V Solis; Luigi D Notarangelo; David V Serreze; Mitsuru Matsumoto; Heather D Hickman; Philip M Murphy; Mark S Anderson; Jean K Lim; Steven M Holland; Scott G Filler; Behdad Afzali; Yasmine Belkaid; Niki M Moutsopoulos; Michail S Lionakis
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

5.  Bourgeoning Scientific Research in Down Syndrome.

Authors:  Dusan Bogunovic
Journal:  J Clin Immunol       Date:  2020-07-25       Impact factor: 8.317

6.  Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes.

Authors:  Carmela Rita Balistreri; Claudia Leonarda Ammoscato; Letizia Scola; Tiziana Fragapane; Rosa Maria Giarratana; Domenico Lio; Maria Piccione
Journal:  Genes (Basel)       Date:  2020-11-28       Impact factor: 4.096

7.  Atypical Inflammatory Syndrome Triggered by SARS-CoV-2 in Infants with Down Syndrome.

Authors:  Louise Malle; Paul Bastard; Andrea Martin-Nalda; Taya Carpenter; Douglas Bush; Roosheel Patel; Roger Colobran; Pere Soler-Palacin; Jean-Laurent Casanova; Melissa Gans; Jacques G Rivière; Dusan Bogunovic
Journal:  J Clin Immunol       Date:  2021-06-05       Impact factor: 8.317

Review 8.  Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Maria Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 9.  Down syndrome and type I interferon: not so simple.

Authors:  Louise Malle; Dusan Bogunovic
Journal:  Curr Opin Immunol       Date:  2021-06-23       Impact factor: 7.268

10.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.

Authors:  Isabelle Meyts; Giorgia Bucciol; Isabella Quinti; Bénédicte Neven; Alain Fischer; Elena Seoane; Eduardo Lopez-Granados; Carla Gianelli; Angel Robles-Marhuenda; Pierre-Yves Jeandel; Catherine Paillard; Vijay G Sankaran; Yesim Yilmaz Demirdag; Vassilios Lougaris; Alessandro Aiuti; Alessandro Plebani; Cinzia Milito; Virgil Ash Dalm; Kissy Guevara-Hoyer; Silvia Sánchez-Ramón; Liliana Bezrodnik; Federica Barzaghi; Luis Ignacio Gonzalez-Granado; Grant R Hayman; Gulbu Uzel; Leonardo Oliveira Mendonça; Carlo Agostini; Giuseppe Spadaro; Raffaele Badolato; Annarosa Soresina; François Vermeulen; Cedric Bosteels; Bart N Lambrecht; Michael Keller; Peter J Mustillo; Roshini S Abraham; Sudhir Gupta; Ahmet Ozen; Elif Karakoc-Aydiner; Safa Baris; Alexandra F Freeman; Marco Yamazaki-Nakashimada; Selma Scheffler-Mendoza; Sara Espinosa-Padilla; Andrew R Gennery; Stephen Jolles; Yazmin Espinosa; M Cecilia Poli; Claire Fieschi; Fabian Hauck; Charlotte Cunningham-Rundles; Nizar Mahlaoui; Klaus Warnatz; Kathleen E Sullivan; Stuart G Tangye
Journal:  J Allergy Clin Immunol       Date:  2020-09-24       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.